BOSTON and PITTSBURGH, March 24, 2016 /PRNewswire/ -- ORIG3N, Inc., a pioneer in regenerative medicine and Sharp Edge Labs, Inc., a drug discovery and development company focused on genetic disorders, today announced that they have entered into a drug discovery alliance. As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders.
Previously, patients only became involved in the drug discovery process at its later stages, when a compound was being tested in clinical trials. The new approach that ORIG3N and Sharp Edge Labs are undertaking will bring patient cells into the drug discovery process much earlier with the intent of creating a truly patient-driven drug discovery pipeline.
"We are now involving patients earlier in the drug discovery process – this is a special moment in medicine." Said Scott Sneddon, CEO of Sharp Edge Labs. "By combining our technologies, we are tailoring treatments for specific patient populations from the very beginning, with the aim of delivering disease modifying agents for diseases of high unmet need."
Sharp Edge Labs focuses on inherited diseases involving defects in protein trafficking, one of the most common cellular defects in genetic disorders. The company has a cellular imaging platform that it uses to screen for drugs that can restore proper trafficking, and has internal programs in Cystic Fibrosis, an inherited form of Parkinson's Disease and Frontotemporal Dementia.
ORIG3N is transforming the future of medicine by building LifeCapsule—the world's largest biorepository of induced pluripotent stem cells (iPSC) from crowd sourced blood samples. ORIG3N is using Nobel Prize-winning technology to reprogram each blood sample into iPSCs, which are then used to grow different cell types including neurons, heart cells and liver cells. These cells offer a powerful tool for accurate disease modeling and drug discovery research.
"A patient's own cells are the best model for understanding how a disease manifests and how it responds to a drug," said Robin Y. Smith, CEO of ORIG3N. "Using iPSC technology accelerates the pace of drug development and is helping us move closer to being able to provide the right drug to the right patient and avoid the trial and error approach that often happens today."
About ORIG3N, Inc.
ORIG3N is leading a transformation in the understanding and treatment of rare, genetically inherited diseases. We've established the world's largest uniformly consented cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity we call LifeCapsule. Thousands of people have already contributed to advancing the future of healthcare—and to safeguarding their own future health. The founders are serial entrepreneurs whose previous venture, ArtusLabs, was acquired by PerkinElmer in 2011.
For more information, visit www.orig3n.com.
About Sharp Edge Labs
Sharp Edge is platform biology company with technology to discover first-in-class compounds that treat the fundamental defect in many genetic diseases: protein trafficking. The company is applying its high-speed assay technology to rare diseases including Cystic Fibrosis and Gaucher's, as well as genetically-identifiable subsets of larger diseases including both Parkinson's and Alzheimer's. The company's team and advisors include current and former Genzyme/Sanofi, Synageva, Shire and Pfizer executives.
For more information, visit www.sharpedgelabs.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orig3n-and-sharp-edge-labs-enter-into-drug-discovery-alliance-300241397.html
SOURCE ORIG3N, Inc.